Tremelimumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Tremelimumab comprises 211 peer-reviewed publications across 15 journals, 21 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, and Small Cell Lung Carcinoma. Most recent publication: Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study., J Clin Oncol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Winquist E, Hotte SJ, Chi K, et al. · Clin Cancer Res · 2025
    PubMed: PMID 39513948 · NCT02788773 · Prostatic Neoplasms
  2. Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
    Suárez C, Larkin JMG, Patel P, et al. · J Clin Oncol · 2023
    PubMed: PMID 36809050 · NCT02819596 (CALYPSO) · Carcinoma, Renal Cell
  3. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma.
    Renouf DJ, Loree JM, Knox JJ, et al. · Nat Commun · 2022
    PubMed: PMID 36028483 · NCT02879318
  4. Epigenetic therapy sensitizes anti-PD-1 refractory head and neck cancers to immunotherapy rechallenge.
    Qin T, Mattox AK, Campbell JS, et al. · J Clin Invest · 2025
    PubMed: PMID 40091844 · NCT03019003 · Head and Neck Neoplasms
  5. Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial.
    Gupta AA, Tinker A, Jonker D, et al. · EClinicalMedicine · 2025
    PubMed: PMID 39737219 · NCT02879162
  6. Targets for immunotherapy of liver cancer.
    Greten TF, Sangro B · J Hepatol · 2025
    PubMed: PMID 28923358 · NCT01853618 · Carcinoma, Hepatocellular
  7. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
    Chen EX, Jonker DJ, Loree JM, et al. · JAMA Oncol · 2021
    PubMed: PMID 32379280 · NCT02870920 · Colorectal Neoplasms
  8. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    Antonia SJ, Villegas A, Daniel D, et al. · N Engl J Med · 2017
    PubMed: PMID 28885881 · NCT05000710 (CORAL-Lung) · Neoplasm Metastasis

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT02352948
ARCTIC
—Overall Survival (OS)
From randomization (Day 1) until death due to any cause, approximately 36 months
Sub-study A: Durvalumab11.7 months
Sub-study A: SoC6.8 months
Sub-study B: Durvalumab+Tremelimumab11.5 months
Sub-study B: SoC8.7 months
NCT02352948
ARCTIC
—Progression-Free Survival (PFS)
Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.
Sub-study A: Durvalumab3.8 months
Sub-study A: SoC2.2 months
Sub-study B: Durvalumab+Tremelimumab3.5 months
Sub-study B: SoC3.5 months
NCT02369874
EAGLE
Head and Neck NeoplasmsOverall Survival (OS)
September 2015 to September 2018 (36 months)
Durvalumab7.6 Months
Durvalumab + Tremelimumab6.5 Months
Standard of Care (SoC)8.3 Months
NCT02453282
MYSTIC
Carcinoma, Non-Small-Cell LungOverall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy
From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).
Durvalumab + Tremelimumab11.9 months
Durvalumab Monotherapy16.3 months
SoC Chemotherapy12.9 months
NCT02453282
MYSTIC
Carcinoma, Non-Small-Cell LungProgression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy
Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
Durvalumab + Tremelimumab3.9 months
SoC Chemotherapy5.4 months
NCT02516241—To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set
From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Combination Therapy15.1 Months
Standard of Care12.1 Months
NCT02516241—To Assess the Efficacy of Durvalumab Monotherapy Versus SoC in Terms of OS in PD-L1-High Analysis Set
From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Monotherapy14.4 Months
Standard of Care12.1 Months
NCT02542293
NEPTUNE
—OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set
From baseline (Day 1, Week 0) until death due to any cause, assessed up to the China cohort DCO date (a maximum of approximately 44 months).
China: Durvalumab + Tremelimumab15.0 months
China: SoC Chemotherapy11.7 months
NCT02542293
NEPTUNE
—Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set
From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global cohort DCO date (a maximum of approximately 44 months).
Global: Durvalumab + Tremelimumab11.7 months
Global: SoC Chemotherapy9.1 months
NCT02551159
KESTREL
Squamous Cell Carcinoma of Head and NeckOverall Survival (OS) Median Duration in the PD-L1 TC/IC High Subgroup
From date of randomization until time of final analysis, an average of approximately 4 years
Durvalumab10.9 Months
Durvalumab + Tremelimumab11.2 Months
Standard of Care (SOC)10.9 Months
NCT02551159
KESTREL
Squamous Cell Carcinoma of Head and NeckOverall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC)
From date of randomization until time of final analysis, an average of approximately 4 years
Durvalumab1 Participants
Durvalumab84 Participants
Durvalumab14 Participants
Durvalumab + Tremelimumab1 Participants
Durvalumab + Tremelimumab27 Participants
Durvalumab + Tremelimumab162 Participants
Standard of Care (SOC)14 Participants
Standard of Care (SOC)3 Participants
Standard of Care (SOC)77 Participants
NCT03043872
CASPIAN
Small Cell Lung CarcinomaOS in the China Cohort; Assessed at China Cohort First Analysis; D + EP Compared With EP
From baseline until death due to any cause. Assessed until China cohort first analysis DCO (maximum of approximately 19 months).
China Cohort: D + EP14.4 months
China Cohort: EP10.9 months
NCT03043872
CASPIAN
Small Cell Lung CarcinomaOS in the China Cohort; Assessed at China Cohort Second Analysis; D + EP Compared With EP and D + T + EP Compared With EP
From baseline until death due to any cause. Assessed until China cohort second analysis DCO (maximum of approximately 29 months).
China Cohort: D + EP14.4 months
China Cohort: D + T + EP16.1 months
China Cohort: EP10.9 months
NCT03043872
CASPIAN
Small Cell Lung CarcinomaOS in the Global Cohort; Assessed at Global Cohort Final Analysis; D + EP Compared With EP and D + T + EP Compared With EP
From baseline until death due to any cause. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).
Global Cohort: D + EP12.9 months
Global Cohort: D + T + EP10.4 months
Global Cohort: EP10.5 months
NCT03043872
CASPIAN
Small Cell Lung CarcinomaOverall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EP
From baseline until death due to any cause. Assessed until global cohort interim analysis DCO (maximum of approximately 23 months).
Global Cohort: D + EP13.0 months
Global Cohort: EP10.3 months
NCT03084471
STRONG
Diabetes Mellitus, Insulin-Dependent, 12Number of Participants With Adverse Events of Special Interest (AESIs)
From screening to safety follow up visit (90 days after last dose), up to approximately 3 years.
AEPI181 participants
AEPI300 participants
AEPI49 participants
AEPI13 participants
AEPI0 participants
AEPI145 participants
AEPI20 participants
AEPI3 participants
AEPI0 participants
AEPI7 participants
AEPI119 participants
AESI21 participants
AESI19 participants
AESI1 participants
AESI12 participants
AESI15 participants
AESI140 participants
AESI191 participants
AESI1 participants
AESI124 participants
AESI14 participants
AESI265 participants
imAE65 participants
imAE32 participants
imAE10 participants
imAE0 participants
imAE10 participants
imAE16 participants
imAE87 participants
imAE0 participants
imAE11 participants
imAE17 participants
imAE97 participants
NCT03164616
POSEIDON
—Overall Survival (OS); D + SoC Compared With SoC Alone
From baseline until death due to any cause. Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months).
D + SoC13.3 months
SoC Alone11.7 months
NCT03164616
POSEIDON
—Progression-Free Survival (PFS); D + SoC Compared With SoC Alone
Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).
D + SoC5.5 months
SoC Alone4.8 months
NCT03298451
HIMALAYA
Carcinoma, HepatocellularOverall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mg
From the date of randomization until death due to any cause, assessed up to the data cut-off date (27Aug2021, to a maximum of approximately 46 months).
Durva 1500 mg16.56 months
Sora 400 mg13.77 months
Treme 300 mg x1 Dose + Durva 1500 mg16.43 months
Treme 75 mg x4 Doses + Durva 1500 mg16.36 months
NCT03703297
ADRIATIC
Lung NeoplasmsDurvalumab Versus Placebo: Overall Survival (OS)
From date of randomization until death due to any cause, up to DCO date 15 January 2024 (a maximum of approximately 1936 days)
Durvalumab55.9 months
Placebo33.4 months
NCT03703297
ADRIATIC
Lung NeoplasmsDurvalumab Versus Placebo: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1
Response evaluations performed every 8 weeks (q8w) ± 1 week up to 72 weeks, then every 12 weeks (q12w) ± 1 week up to 96 weeks, and then every 24 weeks (q24w) thereafter until PD, up to DCO date 15 January 2024 (a maximum of approximately 1936 days)
Durvalumab16.6 months
Placebo9.2 months

Publications by year

1969–2026: 211 publications.

1969
1
1995
1
2000
1
2001
2
2002
1
2006
1
2007
3
2008
4
2009
4
2010
4
2011
3
2012
2
2013
3
2014
3
2015
11
2016
15
2017
12
2018
4
2019
12
2020
8
2021
27
2022
26
2023
17
2024
19
2025
20
2026
7

Publications by indication

Carcinoma, Hepatocellular (65)

  • Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer).
    Future Oncol · 2026 · PMID 42108643 · NCT03298451
  • Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis.
    Liver Cancer · 2026 · PMID 41585428 · NCT03298451
  • Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).
    Ther Adv Med Oncol · 2026 · PMID 41732658 · NCT05844046
  • Targets for immunotherapy of liver cancer.
    J Hepatol · 2025 · PMID 28923358 · NCT01853618
  • Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
    J Hepatol · 2025 · PMID 40222621 · NCT03298451

Carcinoma, Non-Small-Cell Lung (23)

  • Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study.
    Ther Adv Med Oncol · 2025 · PMID 41209621 · NCT06008093
  • INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.
    Cancer Immunol Immunother · 2024 · PMID 38349570 · NCT03693612
  • Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
    J Thorac Oncol · 2023 · PMID 37146752 · NCT02000947
  • Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
    Lancet Oncol · 2022 · PMID 35033226 · NCT02888743
  • Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.
    Lung Cancer · 2022 · PMID 34953624 · NCT02040064

Colorectal Neoplasms (10)

  • Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial.
    J Immunother Cancer · 2024 · PMID 39631846 · NCT02870920
  • Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.
    J Clin Oncol · 2023 · PMID 36007218 · NCT02870920
  • First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.
    Nat Med · 2023 · PMID 37563240 · NCT03202758
  • Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.
    J Immunother Cancer · 2023 · PMID 36754451 · NCT03206073
  • Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.
    ESMO Open · 2023 · PMID 29942666 · NCT03202758

Small Cell Lung Carcinoma (8)

  • Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study.
    Future Oncol · 2025 · PMID 40331625 · NCT03043872
  • Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
    Mol Cancer · 2024 · PMID 38811992 · NCT03043872
  • Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
    J Immunother Cancer · 2021 · PMID 33428583 · NCT02701400
  • Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Lancet Oncol · 2021 · PMID 33285097 · NCT03043872
  • Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Lancet · 2019 · PMID 31590988 · NCT03043872

Squamous Cell Carcinoma of Head and Neck (8)

  • Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
    Cancer Immunol Immunother · 2024 · PMID 38430375 · NCT02551159
  • Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial.
    J Clin Oncol · 2024 · PMID 37699162 · NCT03292250
  • Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study.
    ESMO Open · 2024 · PMID 39043009 · NCT02262741
  • Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma.
    Cancer Med · 2023 · PMID 37489066 · NCT02658214
  • Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer.
    Cancer Med · 2022 · PMID 35611499 · NCT01938612

Neoplasm Metastasis (7)

  • Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort.
    Cancers (Basel) · 2023 · PMID 37444551 · NCT02029001
  • Hypofractionated Irradiation Has Immune Stimulatory Potential and Induces a Timely Restricted Infiltration of Immune Cells in Colon Cancer Tumors.
    Front Immunol · 2022 · PMID 28337197 · NCT05000710
  • Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade.
    Cancer Immunol Res · 2017 · PMID 27262113 · NCT05000710
  • The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership.
    Crit Rev Oncol Hematol · 2017 · PMID 28259287 · NCT05000710
  • Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med · 2017 · PMID 28885881 · NCT05000710

Publications by journal

Trial-results highlights

In studies involving specific cancer types, the median Overall Survival (OS) and Progression-Free Survival (PFS) were reported. For patients with Head and Neck Neoplasms in NCT02369874 (EAGLE), the median OS was 6.5 months for the Durvalumab + Tremelimumab arm, 7.6 months for the Durvalumab arm, and 8.3 months for the Standard of Care (SoC) arm. For Carcinoma, Non-Small-Cell Lung (NSCLC) in the PD-L1 (TC >=25%) analysis set of NCT02453282 (MYSTIC), the median OS was 11.9 months for the Durvalumab + Tremelimumab arm, 16.3 months for the Durvalumab Monotherapy arm, and 12.9 months for the SoC Chemotherapy arm. In the same study, the median PFS was 3.9 months for the Durvalumab + Tremelimumab arm and 5.4 months for the SoC Chemotherapy arm. Additionally, for NSCLC in the China PD-L1 Negative NSCLC analysis set of NCT02542293 (NEPTUNE), the median OS was 15.0 months for the Durvalumab + Tremelimumab arm and 11.7 months for the SoC Chemotherapy arm.

Other studies also investigated outcomes with Durvalumab and Tremelimumab. In Sub-study A of NCT02352948 (ARCTIC), the median OS was 11.7 months for the Durvalumab arm and 6.8 months for the SoC arm, while median PFS was 3.8 months for the Durvalumab arm and 2.2 months for the SoC arm. In Sub-study B of the same study, the median OS was 11.5 months for the Durvalumab + Tremelimumab arm and 8.7 months for the SoC arm. Median PFS was 3.5 months for both the Durvalumab + Tremelimumab arm and the SoC arm in Sub-study B. In NCT02516241, the median OS in the full analysis set was 15.1 months for the Combination Therapy (Durvalumab + Tremelimumab) arm and 12.1 months for the Standard of Care arm. In the PD-L1-High analysis set of NCT02516241, the median OS was 14.4 months for the Monotherapy (Durvalumab) arm and 12.1 months for the Standard of Care arm.

All values presented are sourced from primary registry reporting; individual published papers should be consulted for comprehensive clinical details and decision-making.

All Tremelimumab publications (211)

2026 (7 papers)

  1. Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.
    Thibault C, Bennamoun M, Fléchon A, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 42190158 · NCT03549715 (NEMIO)
  2. Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.
    Senan S, Cho BC, Laktionov KK, et al. · J Thorac Oncol · 2026 · Derived
    PubMed: PMID 41921748 · NCT03703297 (ADRIATIC) · Lung Neoplasms
  3. Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer).
    Rimassa L, Chan SL, Sangro B, et al. · Future Oncol · 2026 · Derived
    PubMed: PMID 42108643 · NCT03298451 (HIMALAYA) · Carcinoma, Hepatocellular
  4. CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.
    Jackson-Spence F, Larkin J, Patel P, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 41861260 · NCT02819596 (CALYPSO) · Carcinoma, Renal Cell
  5. Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis.
    Chan SL, Kudo M, Sangro B, et al. · Liver Cancer · 2026 · Derived
    PubMed: PMID 41585428 · NCT03298451 (HIMALAYA) · Carcinoma, Hepatocellular
  6. Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.
    Capdevila J, Hernando J, Molina-Cerillo J, et al. · Nat Commun · 2026 · Derived
    PubMed: PMID 41935063 · NCT03753919 (DUTHY) · Adenocarcinoma, Follicular
  7. Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).
    Ben Khaled N, Ehmer U, Kubisch I, et al. · Ther Adv Med Oncol · 2026 · Derived
    PubMed: PMID 41732658 · NCT05844046 (MONTBLANC) · Carcinoma, Hepatocellular

2025 (20 papers)

  1. Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Winquist E, Hotte SJ, Chi K, et al. · Clin Cancer Res · 2025 · Trial result
    PubMed: PMID 39513948 · NCT02788773 · Prostatic Neoplasms
  2. Epigenetic therapy sensitizes anti-PD-1 refractory head and neck cancers to immunotherapy rechallenge.
    Qin T, Mattox AK, Campbell JS, et al. · J Clin Invest · 2025 · Trial result
    PubMed: PMID 40091844 · NCT03019003 · Head and Neck Neoplasms
  3. Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial.
    Gupta AA, Tinker A, Jonker D, et al. · EClinicalMedicine · 2025 · Trial result
    PubMed: PMID 39737219 · NCT02879162
  4. Targets for immunotherapy of liver cancer.
    Greten TF, Sangro B · J Hepatol · 2025 · Trial result
    PubMed: PMID 28923358 · NCT01853618 · Carcinoma, Hepatocellular
  5. Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.
    Zenke Y, Shiraishi Y, Goto Y, et al. · Cancer Sci · 2025 · Derived
    PubMed: PMID 40976711 · NCT03703297 (ADRIATIC) · Lung Neoplasms
  6. Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma.
    Tougeron D, Louvet C, Desramé J, et al. · Commun Med (Lond) · 2025 · Derived
    PubMed: PMID 40275077 · NCT03959293 · Stomach Neoplasms
  7. Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study.
    Skoulidis F, Borghaei H, Garon EB, et al. · Ther Adv Med Oncol · 2025 · Derived
    PubMed: PMID 41209621 · NCT06008093 (TRITON) · Carcinoma, Non-Small-Cell Lung
  8. The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity.
    Sibai M, Cervilla S, Grases D, et al. · Cell Rep · 2025 · Derived
    PubMed: PMID 39864059 · NCT03472274 (DUTRENEO) · Urinary Bladder Neoplasms
  9. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
    Rimassa L, Chan SL, Sangro B, et al. · J Hepatol · 2025 · Derived
    PubMed: PMID 40222621 · NCT03298451 (HIMALAYA) · Carcinoma, Hepatocellular
  10. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.
    Peters S, Cho BC, Luft AV, et al. · J Thorac Oncol · 2025 · Derived
    PubMed: PMID 39243945 · NCT03164616 (POSEIDON)
  11. Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study.
    Özgüroğlu M, Goldman JW, Chen Y, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 40331625 · NCT03043872 (CASPIAN) · Small Cell Lung Carcinoma
  12. Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab.
    Myojin Y, Babaei S, Trehan R, et al. · Gut · 2025 · Derived
    PubMed: PMID 39965889 · NCT02821754 · Carcinoma, Hepatocellular
  13. Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy.
    Mitra S, Jang HJ, Kuncheria A, et al. · J Thorac Cardiovasc Surg · 2025 · Derived
    PubMed: PMID 39395787 · NCT02592551 · Mesothelioma
  14. Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.
    Lee KW, Zang DY, Kim HD, et al. · Br J Cancer · 2025 · Derived
    PubMed: PMID 40399487 · NCT03751761 · Stomach Neoplasms
  15. Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE).
    Lee CK, Liao BC, Subramaniam S, et al. · JTO Clin Res Rep · 2025 · Derived
    PubMed: PMID 39877028 · NCT03994393 (ILLUMINATE)
  16. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
    Lau G, Abou-Alfa GK, Cheng AL, et al. · J Hepatol · 2025 · Derived
    PubMed: PMID 39089633 · NCT03298451 (HIMALAYA) · Carcinoma, Hepatocellular
  17. Evolving Therapeutics for Resectable Esophageal Adenocarcinoma.
    Klute KA, Shah MA · J Natl Compr Canc Netw · 2025 · Derived
    PubMed: PMID 40340830 · NCT04817826 (INFINITY) · Stomach Neoplasms
  18. A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer.
    Fitzgerald KJ, Konstantinopoulos P, Matulonis U, et al. · Gynecol Oncol · 2025 · Derived
    PubMed: PMID 40273550 · NCT03277482 · Ovarian Neoplasms
  19. Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study.
    De La Motte Rouge T, Frenel JS, Cropet C, et al. · Breast · 2025 · Derived
    PubMed: PMID 40795480 · NCT03518606 (MOVIE) · Breast Neoplasms
  20. 4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy.
    Cha J, Kim CG, Sim NS, et al. · Cell Rep Med · 2025 · Derived
    PubMed: PMID 41045934 · NCT03737968 · Laryngeal Diseases

2024 (19 papers)

  1. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
    Xie M, Vuko M, Rodriguez-Canales J, et al. · Mol Cancer · 2024 · Derived
    PubMed: PMID 38811992 · NCT03043872 (CASPIAN) · Small Cell Lung Carcinoma
  2. FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.
    Tougeron D, Dahan L, Evesque L, et al. · JAMA Oncol · 2024 · Derived
    PubMed: PMID 38573643 · NCT03959293 · Stomach Neoplasms
  3. Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
    Seiwert TY, Wildsmith S, Fayette J, et al. · Cancer Immunol Immunother · 2024 · Derived
    PubMed: PMID 38430375 · NCT02551159 (KESTREL) · Squamous Cell Carcinoma of Head and Neck
  4. Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.
    Sangro B, Galle PR, Kelley RK, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38805668 · NCT03298451 (HIMALAYA) · Carcinoma, Hepatocellular
  5. FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma.
    Patel TH, Brewer JR, Fan J, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 37676259 · NCT03298451 (HIMALAYA) · Carcinoma, Hepatocellular
  6. Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastases.
    Page DB, Beal K, Linch SN, et al. · NPJ Breast Cancer · 2024 · Derived
    PubMed: PMID 35440655 · NCT02563925 · Breast Neoplasms
  7. Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma.
    Monge C, Xie C, Myojin Y, et al. · Cancer Med · 2024 · Derived
    PubMed: PMID 38205877 · NCT02821754 · Carcinoma, Hepatocellular
  8. Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.
    Miller EJ, Rose TL, Maughan BL, et al. · Cancer · 2024 · Derived
    PubMed: PMID 38180804 · NCT03557918 · Carcinoma, Transitional Cell
  9. Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial.
    Ma LX, Titmuss E, Loree JM, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39631846 · NCT02870920 · Colorectal Neoplasms
  10. Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400).
    Kozono D, Hua X, Wu MC, et al. · J Thorac Oncol · 2024 · Derived
    PubMed: PMID 39111731 · NCT02154490
  11. Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial.
    Keam B, Hong MH, Shin SH, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 37699162 · NCT03292250 · Squamous Cell Carcinoma of Head and Neck
  12. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.
    Hinchcliff EM, Knisely A, Adjei N, et al. · Cancer · 2024 · Derived
    PubMed: PMID 38009662 · NCT03026062 · Ovarian Neoplasms
  13. Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study.
    He JZ, Duval V, Jauslin P, et al. · Clin Pharmacol Ther · 2024 · Derived
    PubMed: PMID 37777827 · NCT03164616 (POSEIDON)
  14. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
    Cheng Y, Spigel DR, Cho BC, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 39268857 · NCT03703297 (ADRIATIC) · Lung Neoplasms
  15. Single-cell analysis reveals cellular and molecular factors counteracting HPV-positive oropharyngeal cancer immunotherapy outcomes.
    Cha J, Kim DH, Kim G, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 38857913 · NCT03737968 · Laryngeal Diseases
  16. Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study.
    Algazi A, Papadopoulos KP, Tsai F, et al. · ESMO Open · 2024 · Derived
    PubMed: PMID 39043009 · NCT02262741 · Squamous Cell Carcinoma of Head and Neck
  17. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
    Abou-Alfa GK, Lau G, Kudo M, et al. · NEJM Evid · 2024 · Derived
    PubMed: PMID 38319892 · NCT03298451 (HIMALAYA) · Carcinoma, Hepatocellular
  18. INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.
    Hilton JF, Ott PA, Hansen AR, et al. · Cancer Immunol Immunother · 2024 · Background
    PubMed: PMID 38349570 · NCT03693612 · Carcinoma, Non-Small-Cell Lung
  19. Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma.
    De Toni EN, Mayerle J, Oehrle B, et al. · Aliment Pharmacol Ther · 2024 · Background
    PubMed: PMID 38643505 · NCT05844046 (MONTBLANC) · Carcinoma, Hepatocellular

2023 (17 papers)

  1. Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
    Suárez C, Larkin JMG, Patel P, et al. · J Clin Oncol · 2023 · Trial result
    PubMed: PMID 36809050 · NCT02819596 (CALYPSO) · Carcinoma, Renal Cell
  2. Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort.
    Trédan O, Toulmonde M, Le Tourneau C, et al. · Cancers (Basel) · 2023 · Derived
    PubMed: PMID 37444551 · NCT02029001 (MOST plus) · Neoplasm Metastasis
  3. Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.
    Topham JT, O'Callaghan CJ, Feilotter H, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36007218 · NCT02870920 · Colorectal Neoplasms
  4. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.
    Thibaudin M, Fumet JD, Chibaudel B, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 37563240 · NCT03202758 (MEDITREME) · Colorectal Neoplasms
  5. Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D.
    Park J, Lee JB, Lim MC, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 37865397 · NCT03899610 (KGOG3046) · Ovarian Neoplasms
  6. Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.
    Monge C, Xie C, Myojin Y, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 36754451 · NCT03206073 · Colorectal Neoplasms
  7. A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.
    Lee HS, Jang HJ, Ramineni M, et al. · Clin Cancer Res · 2023 · Derived
    PubMed: PMID 36469573 · NCT02592551 · Mesothelioma
  8. Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma.
    Lee DH, Kim HR, Keam B, et al. · Cancer Med · 2023 · Derived
    PubMed: PMID 37489066 · NCT02658214 · Squamous Cell Carcinoma of Head and Neck
  9. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
    Johnson ML, Cho BC, Luft A, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36327426 · NCT03164616 (POSEIDON)
  10. Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
    Garon EB, Spira AI, Goldberg SB, et al. · J Thorac Oncol · 2023 · Derived
    PubMed: PMID 37146752 · NCT02000947 (D4190C00006) · Carcinoma, Non-Small-Cell Lung
  11. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
    Gaitskell K, Rogozińska E, Platt S, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37185961 · NCT03699449
  12. Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.
    Fumet JD, Isambert N, Hervieu A, et al. · ESMO Open · 2023 · Derived
    PubMed: PMID 29942666 · NCT03202758 (MEDITREME) · Colorectal Neoplasms
  13. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
    Di Dio C, Bogani G, Di Donato V, et al. · Gynecol Oncol · 2023 · Derived
    PubMed: PMID 36493574 · NCT03015129 · Endometrial Neoplasms
  14. NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer.
    Cheng Y, Zhou Q, Han B, et al. · Lung Cancer · 2023 · Derived
    PubMed: PMID 36806898 · NCT02542293 (NEPTUNE)
  15. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.
    Capdevila J, Hernando J, Teule A, et al. · Nat Commun · 2023 · Derived
    PubMed: PMID 37221181 · NCT03095274 (DUNE) · Neuroendocrine Tumors
  16. First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).
    Autio KA, Higano CS, Nordquist L, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 36948505 · NCT02616185 · Prostatic Neoplasms
  17. Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.
    J Immunother Cancer · 2023 · Derived
    PubMed: PMID 37678916 · NCT03298451 (HIMALAYA) · Carcinoma, Hepatocellular

2022 (26 papers)

  1. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma.
    Renouf DJ, Loree JM, Knox JJ, et al. · Nat Commun · 2022 · Trial result
    PubMed: PMID 36028483 · NCT02879318
  2. CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC.
    Leighl NB, Laurie SA, Goss GD, et al. · J Thorac Oncol · 2022 · Trial result
    PubMed: PMID 34800700 · NCT03057106
  3. Hypofractionated Irradiation Has Immune Stimulatory Potential and Induces a Timely Restricted Infiltration of Immune Cells in Colon Cancer Tumors.
    Frey B, Rückert M, Weber J, et al. · Front Immunol · 2022 · Trial result
    PubMed: PMID 28337197 · NCT05000710 (CORAL-Lung) · Neoplasm Metastasis
  4. Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation.
    van Pul KM, Notohardjo JCL, Fransen MF, et al. · Sci Immunol · 2022 · Derived
    PubMed: PMID 35857579 · NCT04274816 · Melanoma
  5. The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
    Thompson NA, Stewart GD, Welsh SJ, et al. · BMC Cancer · 2022 · Derived
    PubMed: PMID 35073853 · NCT04107168 · Lung Neoplasms
  6. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
    Subudhi SK, Siddiqui BA, Aparicio AM, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 34663638 · NCT03204812 · Prostatic Neoplasms
  7. Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
    Sonpavde GP, Sternberg CN, Loriot Y, et al. · Eur J Cancer · 2022 · Derived
    PubMed: PMID 35042068 · NCT03084471 (STRONG) · Diabetes Mellitus, Insulin-Dependent, 12
  8. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.
    Somaiah N, Conley AP, Parra ER, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35934010 · NCT02815995 · Hemangioendothelioma, Epithelioid
  9. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
    Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35033226 · NCT02888743 · Carcinoma, Non-Small-Cell Lung
  10. Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.
    Riudavets M, Naigeon M, Texier M, et al. · Lung Cancer · 2022 · Derived
    PubMed: PMID 34953624 · NCT02040064 (GEFTREM) · Carcinoma, Non-Small-Cell Lung
  11. Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial.
    Ott PA, Nazzaro M, Pfaff KL, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 34772758 · NCT02141542 · Melanoma
  12. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.
    Oh DY, Lee KH, Lee DW, et al. · Lancet Gastroenterol Hepatol · 2022 · Derived
    PubMed: PMID 35278356 · NCT03046862 · Biliary Tract Neoplasms
  13. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
    O'Reilly EM, Oh DY, Dhani N, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 31318392 · NCT02558894 · Anophthalmia with pulmonary hypoplasia
  14. How patients being treated for non-small cell lung cancer value treatment benefit despite side effects.
    Martin ML, Correll J, Walding A, et al. · Qual Life Res · 2022 · Derived
    PubMed: PMID 34056687 · NCT02352948 (ARCTIC)
  15. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers.
    Maia MC, Salgia M, Pal SK, et al. · Nat Rev Urol · 2022 · Derived
    PubMed: PMID 32203306 · NCT03385655 · Prostatic Neoplasms
  16. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
    Leighl NB, Redman MW, Rizvi N, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 34429332 · NCT03373760
  17. A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer.
    Lee NY, Riaz N, Wu V, et al. · Thyroid · 2022 · Derived
    PubMed: PMID 35521657 · NCT03122496 · Thyroid Carcinoma, Anaplastic
  18. Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial.
    Lee JY, Kim BG, Kim JW, et al. · J Gynecol Oncol · 2022 · Derived
    PubMed: PMID 35320892 · NCT03699449
  19. Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer.
    Hecht M, Eckstein M, Rutzner S, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 35078923 · NCT03426657
  20. Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.
    Goldman JW, Piha-Paul SA, Curti B, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 35699623 · NCT02705482 · Diabetes Mellitus, Insulin-Dependent, 12
  21. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
    Garon EB, Cho BC, Reinmuth N, et al. · Clin Lung Cancer · 2022 · Derived
    PubMed: PMID 33775558 · NCT02453282 (MYSTIC) · Carcinoma, Non-Small-Cell Lung
  22. Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma.
    Fujiwara Y, Takahashi Y, Okada M, et al. · Oncologist · 2022 · Derived
    PubMed: PMID 35671201 · NCT02141347
  23. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
    Falchook GS, Peeters M, Rottey S, et al. · Invest New Drugs · 2022 · Derived
    PubMed: PMID 33852104 · NCT02718911
  24. Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer.
    Doki Y, Ueno M, Hsu CH, et al. · Cancer Med · 2022 · Derived
    PubMed: PMID 35611499 · NCT01938612 · Squamous Cell Carcinoma of Head and Neck
  25. F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial.
    Beck M, Hartwich J, Eckstein M, et al. · Ann Nucl Med · 2022 · Derived
    PubMed: PMID 35534690 · NCT03426657
  26. Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma.
    Pinato DJ, Fessas P, Sapisochin G, et al. · Hepatology · 2022 · Background
    PubMed: PMID 33369758 · NCT05440864 ((NEOTOMA)) · Carcinoma, Hepatocellular

2021 (27 papers)

  1. A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226.
    Juergens RA, Hao D, Ellis PM, et al. · Lung Cancer · 2021 · Trial result
    PubMed: PMID 32169783 · NCT02537418
  2. A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers.
    Edenfield WJ, Chung K, O'Rourke M, et al. · Oncologist · 2021 · Trial result
    PubMed: PMID 33893692 · NCT02938793 · Neoplasms
  3. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
    Chen EX, Jonker DJ, Loree JM, et al. · JAMA Oncol · 2021 · Trial result
    PubMed: PMID 32379280 · NCT02870920 · Colorectal Neoplasms
  4. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade.
    Zhang Q, Luo J, Wu S, et al. · Cancer Discov · 2021 · Derived
    PubMed: PMID 32816849 · NCT02261220
  5. Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study.
    Zamarin D, Hamid O, Nayak-Kapoor A, et al. · Clin Cancer Res · 2021 · Derived
    PubMed: PMID 32586937 · NCT02301130
  6. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
    Senan S, Okamoto I, Lee GW, et al. · Clin Lung Cancer · 2021 · Derived
    PubMed: PMID 31948903 · NCT03703297 (ADRIATIC) · Lung Neoplasms
  7. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
    Rizvi NA, Cho BC, Reinmuth N, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32271377 · NCT02453282 (MYSTIC) · Carcinoma, Non-Small-Cell Lung
  8. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
    Redman MW, Papadimitrakopoulou VA, Minichiello K, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 33125909 · NCT02154490
  9. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
    Powles T, van der Heijden MS, Castellano D, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 32971005 · NCT02516241
  10. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.
    Planchard D, Reinmuth N, Orlov S, et al. · Ann Oncol · 2021 · Derived
    PubMed: PMID 32201234 · NCT02352948 (ARCTIC)
  11. Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
    Pakkala S, Higgins K, Chen Z, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 33428583 · NCT02701400 · Small Cell Lung Carcinoma
  12. RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
    Oza B, Frangou E, Smith B, et al. · Contemp Clin Trials · 2021 · Derived
    PubMed: PMID 34538402 · NCT03288532 (RAMPART) · Carcinoma, Renal Cell
  13. RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting.
    Meade A, Oza B, Frangou E, et al. · Contemp Clin Trials · 2021 · Derived
    PubMed: PMID 34538401 · NCT03288532 (RAMPART) · Carcinoma, Renal Cell
  14. Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials.
    Marconi L, Sun M, Beisland C, et al. · Clin Genitourin Cancer · 2021 · Derived
    PubMed: PMID 33526329 · NCT03288532 (RAMPART) · Carcinoma, Renal Cell
  15. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
    Kelley RK, Sangro B, Harris W, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 34292792 · NCT02519348 · Carcinoma, Hepatocellular
  16. Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
    Hwang M, Seiwert TY · Lancet Oncol · 2021 · Derived
    PubMed: PMID 33684371 · NCT02551159 (KESTREL) · Squamous Cell Carcinoma of Head and Neck
  17. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW, Dvorkin M, Chen Y, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 33285097 · NCT03043872 (CASPIAN) · Small Cell Lung Carcinoma
  18. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.
    Gao J, Navai N, Alhalabi O, et al. · Nat Med · 2021 · Derived
    PubMed: PMID 33046869 · NCT02812420 · Hydronephrosis
  19. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
    Fumet JD, Limagne E, Thibaudin M, et al. · BMC Cancer · 2021 · Derived
    PubMed: PMID 32778095 · NCT04169841 (GUIDE2REPAIR)
  20. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
    Ferris RL, Haddad R, Even C, et al. · Ann Oncol · 2021 · Derived
    PubMed: PMID 32294530 · NCT02369874 (EAGLE) · Head and Neck Neoplasms
  21. Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results.
    Ferrarotto R, Bell D, Rubin ML, et al. · Clin Cancer Res · 2021 · Derived
    PubMed: PMID 32269052 · NCT03144778 · Squamous Cell Carcinoma of Head and Neck
  22. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma.
    Campbell MT, Matin SF, Tam AL, et al. · Nat Commun · 2021 · Derived
    PubMed: PMID 34737281 · NCT02626130 · Carcinoma, Renal Cell
  23. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.
    Calabrò L, Rossi G, Morra A, et al. · Lancet Respir Med · 2021 · Derived
    PubMed: PMID 33844995 · NCT02588131 · Mesothelioma, Malignant
  24. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial.
    Boilève A, Hilmi M, Gougis P, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 33279854 · NCT03704480 (IMMUNO-BIL)
  25. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.
    Antill Y, Kok PS, Robledo K, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 34103352 · NCT03015129 · Endometrial Neoplasms
  26. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities.
    Pardee AD, Butterfield LH · Oncoimmunology · 2021 · Background
    PubMed: PMID 22720211 · NCT05440864 ((NEOTOMA)) · Carcinoma, Hepatocellular
  27. Comparative analysis of outcomes after liver resection and liver transplantation for early stages hepatocellular carcinoma in HIV-infected patients. An intention-to-treat analysis.
    Golse N, Duarte P, Fontana A, et al. · HPB (Oxford) · 2021 · Background
    PubMed: PMID 31734238 · NCT05440864 ((NEOTOMA)) · Carcinoma, Hepatocellular

2020 (8 papers)

  1. Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer.
    Xie C, Duffy AG, Mabry-Hrones D, et al. · Hepatology · 2020 · Trial result
    PubMed: PMID 30578687 · NCT01853618 · Carcinoma, Hepatocellular
  2. Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO.
    Thibault C, Elaidi R, Vano YA, et al. · Bull Cancer · 2020 · Derived
    PubMed: PMID 32620213 · NCT03549715 (NEMIO)
  3. An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION.
    Lee JY, Yi JY, Kim HS, et al. · Jpn J Clin Oncol · 2020 · Derived
    PubMed: PMID 31671191 · NCT03699449
  4. A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D.
    Lee JY, Kim JW, Lim MC, et al. · J Gynecol Oncol · 2020 · Derived
    PubMed: PMID 31576697 · NCT03899610 (KGOG3046) · Ovarian Neoplasms
  5. Exposure-Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status.
    Baverel P, Roskos L, Tatipalli M, et al. · Clin Transl Sci · 2020 · Derived
    PubMed: PMID 30883000 · NCT01843374 (Tremelimumab) · Diabetes Mellitus, Insulin-Dependent, 12
  6. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS, Ryoo BY, Hsu CH, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 32502443 · NCT05440864 ((NEOTOMA)) · Carcinoma, Hepatocellular
  7. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
    Finn RS, Qin S, Ikeda M, et al. · N Engl J Med · 2020 · Background
    PubMed: PMID 32402160 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  8. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
    Chalabi M, Fanchi LF, Dijkstra KK, et al. · Nat Med · 2020 · Background
    PubMed: PMID 32251400 · NCT04817826 (INFINITY) · Stomach Neoplasms

2019 (12 papers)

  1. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.
    Agdashian D, ElGindi M, Xie C, et al. · Cancer Immunol Immunother · 2019 · Trial result
    PubMed: PMID 30688989 · NCT01853618 · Carcinoma, Hepatocellular
  2. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
    Siu LL, Even C, Mesía R, et al. · JAMA Oncol · 2019 · Derived
    PubMed: PMID 30383184 · NCT02319044 · Head and Neck Neoplasms
  3. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Paz-Ares L, Dvorkin M, Chen Y, et al. · Lancet · 2019 · Derived
    PubMed: PMID 31590988 · NCT03043872 (CASPIAN) · Small Cell Lung Carcinoma
  4. An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis.
    Necchi A, Giannatempo P, Raggi D, et al. · Eur Urol · 2019 · Derived
    PubMed: PMID 30243800 · NCT03081923 (APACHE) · Neoplasms, Germ Cell and Embryonal
  5. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
    Calabrò L, Morra A, Giannarelli D, et al. · Lancet Respir Med · 2019 · Derived
    PubMed: PMID 29773326 · NCT02588131 · Mesothelioma, Malignant
  6. Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.
    Bahig H, Aubin F, Stagg J, et al. · BMC Cancer · 2019 · Derived
    PubMed: PMID 30642290 · NCT03283605 · Squamous Cell Carcinoma of Head and Neck
  7. A global view of hepatocellular carcinoma: trends, risk, prevention and management.
    Yang JD, Hainaut P, Gores GJ, et al. · Nat Rev Gastroenterol Hepatol · 2019 · Background
    PubMed: PMID 31439937 · NCT05440864 ((NEOTOMA)) · Carcinoma, Hepatocellular
  8. Percutaneous irreversible electroporation of hepatocellular carcinoma: Contrast-enhanced ultrasound-findings during 1-year follow-up.
    Niessen C, Beyer LP, Haimerl M, et al. · Clin Hemorheol Microcirc · 2019 · Background
    PubMed: PMID 30584122 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  9. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.
    Nault JC, Sutter O, Nahon P, et al. · J Hepatol · 2019 · Background
    PubMed: PMID 29031662 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  10. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.
    European Association for the Study of the Liver · J Hepatol · 2019 · Background
    PubMed: PMID 29628281 · NCT05440864 ((NEOTOMA)) · Carcinoma, Hepatocellular
  11. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma.
    Chiang CL, Chan MKH, Yeung CSY, et al. · Strahlenther Onkol · 2019 · Background
    PubMed: PMID 30413833 · NCT04988945 · Carcinoma, Hepatocellular
  12. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
    Arce Vargas F, Furness AJS, Litchfield K, et al. · Cancer Cell · 2019 · Background
    PubMed: PMID 29576375 · NCT05440864 ((NEOTOMA)) · Carcinoma, Hepatocellular

2018 (4 papers)

  1. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
    Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. · J Hepatol · 2018 · Trial result
    PubMed: PMID 27816492 · NCT01853618 · Carcinoma, Hepatocellular
  2. Percutaneous Irreversible Electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors.
    Niessen C, Thumann S, Beyer L, et al. · Sci Rep · 2018 · Background
    PubMed: PMID 28266600 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  3. Hepatocellular carcinoma.
    Forner A, Reig M, Bruix J, et al. · Lancet · 2018 · Background
    PubMed: PMID 29307467 · NCT05440864 ((NEOTOMA)) · Carcinoma, Hepatocellular
  4. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    El-Khoueiry AB, Sangro B, Yau T, et al. · Lancet · 2018 · Background
    PubMed: PMID 28434648 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular

2017 (12 papers)

  1. Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade.
    McNamara MJ, Hilgart-Martiszus I, Barragan Echenique DM, et al. · Cancer Immunol Res · 2017 · Trial result
    PubMed: PMID 27262113 · NCT05000710 (CORAL-Lung) · Neoplasm Metastasis
  2. The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership.
    Chajon E, Castelli J, Marsiglia H, et al. · Crit Rev Oncol Hematol · 2017 · Trial result
    PubMed: PMID 28259287 · NCT05000710 (CORAL-Lung) · Neoplasm Metastasis
  3. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    Antonia SJ, Villegas A, Daniel D, et al. · N Engl J Med · 2017 · Trial result
    PubMed: PMID 28885881 · NCT05000710 (CORAL-Lung) · Neoplasm Metastasis
  4. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
    Maio M, Scherpereel A, Calabrò L, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28729154 · NCT01843374 (Tremelimumab) · Diabetes Mellitus, Insulin-Dependent, 12
  5. Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series.
    Sutter O, Calvo J, N'Kontchou G, et al. · Radiology · 2017 · Background
    PubMed: PMID 28453431 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  6. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    Rizvi NA, Hellmann MD, Brahmer JR, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 27354481 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung
  7. Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.
    Qin A, Coffey DG, Warren EH, et al. · Cancer Med · 2017 · Background
    PubMed: PMID 27416962 · NCT05440864 ((NEOTOMA)) · Carcinoma, Hepatocellular
  8. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Langer CJ, Gadgeel SM, Borghaei H, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 27745820 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung
  9. Immunogenic cell death in cancer and infectious disease.
    Galluzzi L, Buqué A, Kepp O, et al. · Nat Rev Immunol · 2017 · Background
    PubMed: PMID 27748397 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung
  10. Irreversible Electroporation versus Radiofrequency Ablation: A Comparison of Local and Systemic Effects in a Small-Animal Model.
    Bulvik BE, Rozenblum N, Gourevich S, et al. · Radiology · 2017 · Background
    PubMed: PMID 27429143 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  11. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC).
    Bhutiani N, Philips P, Scoggins CR, et al. · HPB (Oxford) · 2017 · Background
    PubMed: PMID 27346140 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  12. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
    Bernstein MB, Krishnan S, Hodge JW, et al. · Nat Rev Clin Oncol · 2017 · Background
    PubMed: PMID 26951040 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung

2016 (15 papers)

  1. The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.
    Middleton G, Crack LR, Popat S, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 26410619 · NCT02154490
  2. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
    Calabrò L, Morra A, Fonsatti E, et al. · Lancet Respir Med · 2016 · Derived
    PubMed: PMID 25819643 · NCT01655888 · Mesothelioma, Malignant
  3. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
    Antonia S, Goldberg SB, Balmanoukian A, et al. · Lancet Oncol · 2016 · Derived
    PubMed: PMID 26858122 · NCT02000947 (D4190C00006) · Carcinoma, Non-Small-Cell Lung
  4. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
    Stewart R, Morrow M, Hammond SA, et al. · Cancer Immunol Res · 2016 · Background
    PubMed: PMID 25943534 · NCT04988945 · Carcinoma, Hepatocellular
  5. Cancer statistics, 2016.
    Siegel RL, Miller KD, Jemal A, et al. · CA Cancer J Clin · 2016 · Background
    PubMed: PMID 26742998 · NCT03085849 · Small Cell Lung Carcinoma
  6. Ablative therapies: Advantages and disadvantages of radiofrequency, cryotherapy, microwave and electroporation methods, or how to choose the right method for an individual patient?
    Seror O · Diagn Interv Imaging · 2016 · Background
    PubMed: PMID 25981214 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  7. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
    Reck M, Rodríguez-Abreu D, Robinson AG, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27718847 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung
  8. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
    Rajani KR, Vile RG · Viruses · 2016 · Background
    PubMed: PMID 26580645 · NCT03206073 · Colorectal Neoplasms
  9. Percutaneous Ablation of Hepatic Tumors Using Irreversible Electroporation: A Prospective Safety and Midterm Efficacy Study in 34 Patients.
    Niessen C, Beyer LP, Pregler B, et al. · J Vasc Interv Radiol · 2016 · Background
    PubMed: PMID 26922979 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  10. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
    Kohlhapp FJ, Kaufman HL · Clin Cancer Res · 2016 · Background
    PubMed: PMID 26719429 · NCT03206073 · Colorectal Neoplasms
  11. Current clinical trials testing the combination of immunotherapy with radiotherapy.
    Kang J, Demaria S, Formenti S, et al. · J Immunother Cancer · 2016 · Background
    PubMed: PMID 27660705 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung
  12. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
    Herbst RS, Baas P, Kim DW, et al. · Lancet · 2016 · Background
    PubMed: PMID 26712084 · NCT03130764 · Carcinoma, Non-Small-Cell Lung
  13. Irreversible Electroporation Can Effectively Ablate Hepatocellular Carcinoma to Complete Pathologic Necrosis.
    Cheng RG, Bhattacharya R, Yeh MM, et al. · J Vasc Interv Radiol · 2016 · Background
    PubMed: PMID 26119204 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  14. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J, Takayama T, Mazzaferro V, et al. · Lancet Oncol · 2016 · Background
    PubMed: PMID 26361969 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  15. Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation.
    Behm B, Di Fazio P, Michl P, et al. · Gut · 2016 · Background
    PubMed: PMID 25524262 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular

2015 (11 papers)

  1. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
    Vétizou M, Pitt JM, Daillère R, et al. · Science · 2015 · Trial result
    PubMed: PMID 26541610 · NCT05000710 (CORAL-Lung) · Neoplasm Metastasis
  2. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
    Twyman-Saint Victor C, Rech AJ, Maity A, et al. · Nature · 2015 · Background
    PubMed: PMID 25754329 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung
  3. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).
    Trinchet JC, Bourcier V, Chaffaut C, et al. · Hepatology · 2015 · Background
    PubMed: PMID 25678021 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  4. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis.
    Tabrizian P, Jibara G, Shrager B, et al. · Ann Surg · 2015 · Background
    PubMed: PMID 25010665 · NCT05440864 ((NEOTOMA)) · Carcinoma, Hepatocellular
  5. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
    Schadendorf D, Hodi FS, Robert C, et al. · J Clin Oncol · 2015 · Background
    PubMed: PMID 25667295 · NCT04988945 · Carcinoma, Hepatocellular
  6. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
    Rizvi NA, Mazières J, Planchard D, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25704439 · NCT05440864 ((NEOTOMA)) · Carcinoma, Hepatocellular
  7. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
    Lee JH, Lee JH, Lim YS, et al. · Gastroenterology · 2015 · Background
    PubMed: PMID 25747273 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  8. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.
    Golden EB, Chhabra A, Chachoua A, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 26095785 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung
  9. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
    Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25840693 · NCT03130764 · Carcinoma, Non-Small-Cell Lung
  10. CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
    Calabrò L, Ceresoli GL, di Pietro A, et al. · Cancer Immunol Immunother · 2015 · Background
    PubMed: PMID 25233793 · NCT02588131 · Mesothelioma, Malignant
  11. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Borghaei H, Paz-Ares L, Horn L, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 26412456 · NCT03130764 · Carcinoma, Non-Small-Cell Lung

2014 (3 papers)

  1. Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy.
    Klug F, Prakash H, Huber PE, et al. · Cancer Cell · 2014 · Trial result
    PubMed: PMID 24209604 · NCT05000710 (CORAL-Lung) · Neoplasm Metastasis
  2. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
    Sangro B, Gomez-Martin C, de la Mata M, et al. · J Hepatol · 2014 · Background
    PubMed: PMID 23466307 · NCT02821754 · Carcinoma, Hepatocellular
  3. Immunological off-target effects of standard treatments in gastrointestinal cancers.
    Duffy AG, Greten TF · Ann Oncol · 2014 · Background
    PubMed: PMID 24201974 · NCT02821754 · Carcinoma, Hepatocellular

2013 (3 papers)

  1. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
    Calabrò L, Morra A, Fonsatti E, et al. · Lancet Oncol · 2013 · Derived
    PubMed: PMID 24035405 · NCT01649024 · Mesothelioma, Malignant
  2. Nivolumab plus ipilimumab in advanced melanoma.
    Wolchok JD, Kluger H, Callahan MK, et al. · N Engl J Med · 2013 · Background
    PubMed: PMID 23724867 · NCT04988945 · Carcinoma, Hepatocellular
  3. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
    Heo J, Reid T, Ruo L, et al. · Nat Med · 2013 · Background
    PubMed: PMID 23396206 · NCT03206073 · Colorectal Neoplasms

2012 (2 papers)

  1. The blockade of immune checkpoints in cancer immunotherapy.
    Pardoll DM · Nat Rev Cancer · 2012 · Background
    PubMed: PMID 22437870 · NCT05440864 ((NEOTOMA)) · Carcinoma, Hepatocellular
  2. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
    Brahmer JR, Tykodi SS, Chow LQ, et al. · N Engl J Med · 2012 · Background
    PubMed: PMID 22658128 · NCT02821754 · Carcinoma, Hepatocellular

2011 (3 papers)

  1. Oligometastases revisited.
    Weichselbaum RR, Hellman S · Nat Rev Clin Oncol · 2011 · Background
    PubMed: PMID 21423255 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung
  2. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
    Ferlay J, Shin HR, Bray F, et al. · Int J Cancer · 2011 · Background
    PubMed: PMID 21351269 · NCT03130764 · Carcinoma, Non-Small-Cell Lung
  3. Potential of immunotherapy for hepatocellular carcinoma.
    Breous E, Thimme R · J Hepatol · 2011 · Background
    PubMed: PMID 21145836 · NCT05440864 ((NEOTOMA)) · Carcinoma, Hepatocellular

2010 (4 papers)

  1. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response.
    Zerbini A, Pilli M, Laccabue D, et al. · Gastroenterology · 2010 · Background
    PubMed: PMID 20060829 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  2. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
    Wolchok JD, Hoos A, O'Day S, et al. · Clin Cancer Res · 2010 · Background
    PubMed: PMID 19934295 · NCT01975831 · Colorectal Neoplasms
  3. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Kantoff PW, Higano CS, Shore ND, et al. · N Engl J Med · 2010 · Background
    PubMed: PMID 20818862 · NCT01853618 · Carcinoma, Hepatocellular
  4. Antitumor effect after radiofrequency ablation of murine hepatoma is augmented by an active variant of CC Chemokine ligand 3/macrophage inflammatory protein-1alpha.
    Iida N, Nakamoto Y, Baba T, et al. · Cancer Res · 2010 · Background
    PubMed: PMID 20663902 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular

2009 (4 papers)

  1. Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV.
    Zhang C, Wu S, Xue X, et al. · Cytotherapy · 2009 · Background
    PubMed: PMID 18841514 · NCT05440864 ((NEOTOMA)) · Carcinoma, Hepatocellular
  2. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis.
    N'Kontchou G, Mahamoudi A, Aout M, et al. · Hepatology · 2009 · Background
    PubMed: PMID 19731239 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  3. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.
    Gao Q, Wang XY, Qiu SJ, et al. · Clin Cancer Res · 2009 · Background
    PubMed: PMID 19188168 · NCT05440864 ((NEOTOMA)) · Carcinoma, Hepatocellular
  4. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
    Eisenhauer EA, Therasse P, Bogaerts J, et al. · Eur J Cancer · 2009 · Background
    PubMed: PMID 19097774 · NCT03007407

2008 (4 papers)

  1. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.
    Tarhini AA, Kirkwood JM · Expert Opin Biol Ther · 2008 · Background
    PubMed: PMID 18774925 · NCT04988945 · Carcinoma, Hepatocellular
  2. Large (>or=5.0-cm) HCCs: multipolar RF ablation with three internally cooled bipolar electrodes--initial experience in 26 patients.
    Seror O, N'Kontchou G, Ibraheem M, et al. · Radiology · 2008 · Background
    PubMed: PMID 18483229 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  3. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM, Di Bisceglie AM, Bruix J, et al. · J Natl Cancer Inst · 2008 · Background
    PubMed: PMID 18477802 · NCT01853618 · Carcinoma, Hepatocellular
  4. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
    Fife BT, Bluestone JA · Immunol Rev · 2008 · Background
    PubMed: PMID 18759926 · NCT04988945 · Carcinoma, Hepatocellular

2007 (3 papers)

  1. Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation.
    Reyes-Gibby CC, Chan W, Abbruzzese JL, et al. · J Pain Symptom Manage · 2007 · Background
    PubMed: PMID 17513082 · NCT02311361 · Pancreatic Neoplasms
  2. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
    Moore MJ, Goldstein D, Hamm J, et al. · J Clin Oncol · 2007 · Background
    PubMed: PMID 17452677 · NCT02311361 · Pancreatic Neoplasms
  3. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.
    Goldstraw P, Crowley J, Chansky K, et al. · J Thorac Oncol · 2007 · Background
    PubMed: PMID 17762336 · NCT03130764 · Carcinoma, Non-Small-Cell Lung

2006 (1 paper)

  1. Radiation therapy for hepatocellular carcinoma: from palliation to cure.
    Hawkins MA, Dawson LA · Cancer · 2006 · Background
    PubMed: PMID 16541431 · NCT04988945 · Carcinoma, Hepatocellular

2002 (1 paper)

  1. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America.
    Jänne PA, Freidlin B, Saxman S, et al. · Cancer · 2002 · Background
    PubMed: PMID 12237922 · NCT03085849 · Small Cell Lung Carcinoma

2001 (2 papers)

  1. Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma.
    Seong J, Kim SH, Suh CO, et al. · J Gastroenterol Hepatol · 2001 · Background
    PubMed: PMID 11555102 · NCT04988945 · Carcinoma, Hepatocellular
  2. Estimating the world cancer burden: Globocan 2000.
    Parkin DM, Bray F, Ferlay J, et al. · Int J Cancer · 2001 · Background
    PubMed: PMID 11668491 · NCT01853618 · Carcinoma, Hepatocellular

2000 (1 paper)

  1. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress.
    Chute JP, Chen T, Feigal E, et al. · J Clin Oncol · 2000 · Background
    PubMed: PMID 10561217 · NCT03085849 · Small Cell Lung Carcinoma

1995 (1 paper)

  1. Oligometastases.
    Hellman S, Weichselbaum RR · J Clin Oncol · 1995 · Background
    PubMed: PMID 7799047 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung

1969 (1 paper)

  1. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer.
    Moertel CG, Childs DS, Reitemeier RJ, et al. · Lancet · 1969 · Background
    PubMed: PMID 4186452 · NCT02311361 · Pancreatic Neoplasms

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).